As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, ...